Molecular Diagnostics News and Research

RSS

Adnavance Technologies to present its DNA direct detection technology at the AdvaMed 2009

Adnavance Technologies Inc., a developer of direct detection molecular diagnostic tests for medical applications, announced today that Randy White, Ph.D. chief executive officer, will present initial data supporting direct detection of DNA targets in human clinical samples during company presentations.

8 Oct 2009

NIH grants over $3.8 million to Asuragen

Asuragen, Inc. announced today that it has received over $3.8 million in new grant funding for 2009 from the Small Business Innovative Research (SBIR), Small Business Technology Transfer (STTR), and American Recovery and Reinvestment Act (ARRA) funded initiatives of the National Institutes of Health (NIH) to further its development of molecular diagnostics for oncology and genetic disease.

8 Oct 2009

Gen-Probe to acquire Prodesse for $60 million in cash

Gen-Probe Incorporated announced today that it has signed a definitive agreement to acquire Prodesse, Inc., a privately held leader in molecular testing for influenza and other infectious diseases, for approximately $60 million in cash. Gen-Probe's purchase price could increase to up to $85 million if Prodesse achieves certain financial and regulatory milestones in 2010 and 2011.

7 Oct 2009

Arrayit deploys new proteomics platform

Arrayit Corporation, a life sciences and health care technology innovator, announces that on October 1st, 2009, the company deployed its next-generation proteomics platform to customers working in the areas of proteomics and in vitro molecular diagnostics.

5 Oct 2009

PrimeraDx receives its fourth patent

PrimeraDx, Inc., a privately held molecular diagnostics company, announced today that it has received its fourth patent. The patent, entitled “Methods and systems for dynamic gene expression profiling”, with inventor Vladimir Slepnev, Ph.D., describes a novel method of quantitative analysis of gene expression allowing simultaneous interrogation of multiple genes in a single tube reaction.

5 Oct 2009

Advanced Liquid Logic awarded an NIAID contract to develop a rapid HIV diagnostic device

Advanced Liquid Logic announced today that it has received a large, four-year contract from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, for the development of a rapid, point-of-care, diagnostic device for the detection of HIV in low resource settings.

3 Oct 2009

Respiragene test for lung cancer motivates smokers to quit smoking

Smokers who learn their personal risk of lung cancer through gene-based risk assessment are more likely to be motivated to quit their habit, according to Dr. W. Jeffrey Allard, clinical affairs director of Synergenz Bioscience Ltd.

1 Oct 2009

New microchip to detect type and severity of cancer

UofT researchers have used nanomaterials to develop a microchip sensitive enough to quickly determine the type and severity of a patient's cancer so that the disease can be detected earlier for more effective treatment.

29 Sep 2009

Axial Biotech's SCOLISCORE AIS Prognostic Test now available in the U.S.

Axial Biotech, Inc., a company personalizing spine care through the development of molecular diagnostics, announced today that its SCOLISCORE(TM) AIS Prognostic Test is now being made available to spine specialists in the United States. SCOLISCORE is a saliva-based genetic test designed to predict the risk of progression of scoliosis, an abnormal lateral curvature of the spine.

24 Sep 2009

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world.

From QIAGEN Manchester Limited 24 Sep 2009

Primeradx raises funds for commercialization of their technology

PrimeraDx, Inc., a privately held molecular diagnostics company, announced today that it has closed on its $20 million Series C financing. The financing was led by CHL Medical Partners and also included significant participation by many of the Company’s existing investors; Abingworth, InterWest Partners, Malaysian Technology Development Corporation, MPM Capital, Burrill & Company and the Invus Group.

21 Sep 2009

Health Discovery Corporation appoints new COO

Health Discovery Corporation, a personalized medicine company specializing in molecular diagnostics including gene-based testing, as well as computer assisted diagnostics in digital pathology and radiology, announced that former Deputy FDA Commissioner John A. Norris has been appointed as Chief Operating Officer (COO) of the Company.

19 Sep 2009

Targeted Molecular Diagnostics to offer digital pathology services in Beijing

Targeted Molecular Diagnostics (TMD), a Quintiles Central Laboratory, announced today the availability of digital pathology services in Beijing, China. The services add to Quintiles offerings used in the development of therapies to treat the world’s most pressing health issues, including cancer.

15 Sep 2009

Quest Diagnostics' OVA1 ovarian cancer test cleared by the FDA

The U.S. Food and Drug Administration (FDA) today cleared the OVA1(TM) Test, the first blood test that, prior to surgery, can help physicians determine if a woman is at risk for a malignant pelvic mass. OVA1 is the first FDA-cleared laboratory test that can indicate the likelihood of ovarian cancer with high sensitivity prior to biopsy or exploratory surgery, even if radiological test results fail to indicate malignancy.

From Quest Diagnostics 14 Sep 2009

Vitapath Genetics closes $6 million series A round of funding

VitaPath Genetics, a molecular diagnostics company, announced today that it has closed a $6 million series A round of funding led by MDV-Mohr Davidow Ventures. VitaPath was originally seeded by X/Seed Capital, which also co-invested in the Series A. Concurrent with the financing MDV's Michael Goldberg and X/Seed's Michael Borrus took seats on the company's board.

11 Sep 2009

QIAGEN's new QIAsafe DNA blood products launched

Biomatrica, Inc. and QIAGEN announce the launch of QIAGEN's new QIAsafe DNA Blood Products, the first dry blood storage available on a matrix based on Biomatrica's innovative SampleMatrix(R) technology.

From QIAGEN Manchester Limited 10 Sep 2009

Second-quarter fiscal 2009 results announced by Rosetta Genomics

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, today reported financial results for the three and six months ended June 30, 2009.

9 Sep 2009

Rosetta Genomics and AXA Diagnostics sign exclusive distribution agreement

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, and AXA Diagnostics, a privately owned company that markets specialized diagnostic tests, announced today the signing of an exclusive distribution agreement in Italy for Rosetta Genomics’ three currently available diagnostic tests.

8 Sep 2009

New H1N1 Influenza detection test used to diagnose Australia's first swine flu victim

When the first cases of H1N1 Influenza (swine flu) were reported in Mexico in April, UQ researchers got to work developing a test to diagnose the virus.

4 Sep 2009

FDA approves new xTAG Cystic Fibrosis 39 Kit v2 from Luminex

Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new cystic fibrosis (CF) test: the xTAG® Cystic Fibrosis 39 Kit v2.

From Thermo Fisher Scientific Inc. 4 Sep 2009